MyHealthChecked plc
("MyHealthChecked" or "the Company")
Result of AGM
MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
| Resolution (*indicates special resolution) | Votes for1 | % of shares voted2 | Votes against3 | % of shares voted |
| Resolution 1 | 124,644,993 | 100% | 0 | 0% |
| Resolution 2 | 124,233,134 | 99.65% | 436,859 | 0.35% |
| Resolution 3 | 124,534,993 | 99.89% | 135,000 | 0.11% |
| Resolution 4 | 124,534,993 | 99.89% | 135,000 | 0.11% |
| Resolution 5 | 120,470,480 | 96.63% | 4,199,513 | 3.37% |
| Resolution 6* | 120,432,091 | 99.37% | 759,001 | 0.63% |
Notes:
1 Any proxy appointments which gave discretion to the Chairman have been included in the "for" total.
2 As a percentage of the aggregate of votes "for" plus votes "against".
3 An abstention is not counted towards the votes cast "for" or "against" a resolution.
For further information contact:
| MyHealthChecked plc | ||
| Penny McCormick, Chief Executive Officer | via Walbrook PR | |
| | | |
| SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 | |
| Neil Baldwin | | |
| | | |
| Oberon Capital Ltd (Broker) | Tel: +44 (0)203 179 5344 | |
| Mike Seabrook | ||
| | | |
| Walbrook PR Ltd (Media & IR) | Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com | |
| Paul McManus / Alice Woodings | Mob: +44(0)7980 541 893 / +44(0) 7407 804 654 | |
About MyHealthChecked PLC (www.myhealthcheckedplc.com)
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.
MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the acquisition of The Genome Store in November 2020. The tests will be made available online, and would be viable for over the counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
